Biocompatibility of Degradable Stents Constructed Different Biomaterials

Abstract:

Placement for the treatment of coronary atherosclerotic heart disease (CHD) underwent four revolutionary simple balloon dilatation era, bare-metal stent era, drug stent era and completely biodegradable stent era. Completely biodegradable stent is Current research focus. A computer based search of EMbase (1980-01/2011-12), MEDLINE(1966-01/2011-12), CBM(1978-01/2011-08), PubMed (1999-01/2011-12) and CNKI (1999-01/2011-12) was performed. The keywords weredegradable,stents,biocompatibilityin Chinese and English. Indicators including endothelialization degree of coronary artery and incidence of in-stent restenosis were evaluated. 36 articles were included in the final analysis among 262 articles . We systematically evaluated the biocompatibility of vascular stents constructed different biomaterials in these articles and concluded degradable stents may temporarily support vessel wall, smoothly keep blood flow,inhibit thrombosis in an early stage and newborn endomembrane proliferation in later stage and effectively prevent acute vascular occlusion and reduce incidence of restenosis following stent implantation. Biodegradable stents have good biocompatibility and broad application prospects.

• Periodical: Key Engineering Materials (Volumes 575-576)
• Pages: 287-290
• DOI: https://doi.org/10.4028/www.scientific.net/KEM.575-576.287
• Online since: September 2013
• Authors: Chun Hua Ma
• Keywords: Biocompatibility, Degradable, Stents

References

[1] Byrne R A，Sarafoff N，Kastrati A，et al,. Drug-eluting stents in percutane-ous coronary intervention: a benefit-risk assessment. Drug Saf, 2009, 32(9): 749-760.

DOI: 10.2165/11316500-000000000-00000

[2] Finn A V，Nakazawa G，Kolodgie FD，et al. Temporal course of neointimal formation after drug-eluting stent placement: is our understanding of rest-enosis changing. JACC Cardiovasc Interv, 2009, 2(4): 300-302.

DOI: 10.1016/j.jcin.2009.04.009

[3] Baoxin Ma, Ying Xu , Xianliang Liu, Suisheng Wu. The system evaluation of efficacy and safety in biodegradable drug-eluting stents . Chinese Journal of Gerontology, 2011, 31 (10) : 3883-3886.

[4] Hu Rong, Yali Wang. The properties, biocompatibility and complications implantated in coronary stent materials. Tissue engineering research and clinical rehabilitation, 2010, 14(16): 2999-3002.

[5] Fuqiang Huang, Zhentao Yu, Lijuan Luo, The study progress of titanium alloy intravascular stent. Titanium Industry Progress, 2007, 24(1): 29.

[6] Tepe G, Schmehl J, Wendel H P, et al. The biocompatibility of nitinol stents-in vitro evaluation of different surface modi-fications and coatings. Biomaterials, 2006, 27(4): 643.

DOI: 10.1016/j.biomaterials.2005.06.004

[7] Leng Y X, Chen J Y, Huang N, et al. The biocompatibility of the tantalum and tantalum oxide films synthesized by pulse metal vacuum arc source deposition. Nucl Instrum Methods Phys Res, 2006, 242: 30.

DOI: 10.1016/j.nimb.2005.08.002

[8] Zhangqi Liu, Chunliang Li. stent surface modification and intimal hyperplasia. Tissue engineering research and clinical rehabilitation, 2010, 14(25): 4721-4724.

[9] Xuchen Zhou, Dingyi Zeng, Qigang Guan, et al. Rapamycin and paclitaxel-eluting stents quantitative coronary angiography study of small pig early coronary artery inflammatory stenosis. Chinese Circulation Journal, 2006, 21(4): 262-265.

[10] Huiqiang Zhao, Wenyi Guo , Guoliang Jia, etc. The affect of Rapamycin and paclitaxel-eluting stents on blood inflammatory cytokines in patients with coronary heart disease after coronary intervention surgery [J]. Chinese Circulation Journal, 2005, 20(2): 98-100.

[11] Fanrong Diao , Anlin Lv , Junjie Li . The experimental study of rapamycin - tirofiban composite drug-eluting stents to prevent stent thrombosis and restenosis. Chinese Heart Journal, 2007, 19(4): 385-387.

[12] Yanchao Zhao, Xuebo Liu, Junbo Ge, et al. The study of Preparation and biocompatibility in Novel biodegradable cardiovascular eluting stents. Chinese Journal of Biomedical Engineering, 2008, 27(3): 438-442.

[13] Chunli Song, Jichang Zhang, Yang Xue Li, The intimal hyperplasia of canine coronary with estradiol biodegradable coated stent. Chinese Journal of Laboratory Diagnosis, 2011, 15(5): 772-775.

[14] Shu Ding, Genshan Ma. The clinical application progress of drug-eluting stents in the prevention of in-stent restenosis. Journal of Southeast University (Medical Science Edition), 2005, 24(2): 122-125.

[15] Yuyu Wu, Qingjun You, Xiaowei Qi . The experimental study of the biodegradable PDS stent in dogs. Shandong Medical Journal, 2009, 29(6): 40.

[16] Fully biodegradable stents the fourth revolution of coronary intervention. Practical Journal of Cardiac Cerebral Pneumal and Vascular, 2011, 19(6): 1027-1028.

[17] Erbel R. Progress AMS I Clinical Study. Late BreakingClinical Trials. Presented at ACC2006, Atlanta, G A.

[18] Chi Li, Yan Tang, Lili Tan, Preparation of and performance of biodegradable drug coating magnesium alloy surface. Chinese Journal of Materials Research, 2009, 23 (3): 300-303.

[19] Vogt F, Stein A, Rettemeier G, et al. Long-term assess-ment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J, 2004, 25(15): 1330-1334.

DOI: 10.1016/j.ehj.2004.06.010